Attention Laurel Patients:  The new Laurel office is open. The address is 7140 Contee Road, Suite 3500, Laurel, MD 20707….Attention Lanham Patients: Our new Largo office will be opening Monday,  June 17th and our Lanham location will be closed permanently. Largo’s address is 9333 Healthcare Way Suite 4100 Largo, MD 20774.

Trial Protocol ID
D8227C00002_ACRUE

Investigator
John Wallmark, M.D.

A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)

Trial Protocol ID
USOR 18263_BGB-3111-215 *STAR*

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib

Trial Protocol ID
BGB-11417-201

Investigator
Mohit Narang, M.D.

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of
Bcl-2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Trial Protocol ID
USOR 22041_M23-362

Investigator
Syed Shahid Mahmood, M.D.

A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting

Trial Protocol ID
RGX-104-001

Investigator
John Wallmark, M.D.

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies